채혈 기기 시장 : 시장 예측(2026-2032년)

The Blood Collection Devices Market is projected to grow by USD 12.43 billion at a CAGR of 6.14% by 2032.

Blood Collection Devices Executive Summary

Blood collection devices are foundational to diagnostics, transfusion medicine, clinical research, blood banking, and routine patient monitoring. The category includes needles and safety needles, evacuated blood collection tubes, syringes, lancets, blood bags, collection sets, holders, microcollection systems, and related accessories used across hospitals, diagnostic laboratories, ambulatory care centers, emergency departments, and home-based testing environments. Demand is shaped by the global burden of chronic and infectious diseases, expanding preventive screening programs, increasing surgical volumes, blood donation requirements, and the growing use of laboratory testing to guide evidence-based clinical decisions.

Industry priorities are moving beyond basic sample acquisition toward safer, faster, and more reliable preanalytical workflows. Regulatory emphasis on needlestick injury prevention, specimen integrity, traceability, hemolysis reduction, and infection control is accelerating adoption of safety-engineered and closed blood collection systems. At the same time, laboratory automation, point-of-care diagnostics, decentralized clinical trials, and patient-centric care models are reshaping device design and procurement criteria. For stakeholders across the blood collection devices ecosystem, competitiveness increasingly depends on product reliability, usability, compliance readiness, supply continuity, and integration with digital healthcare workflows.

Transformative Shifts in the Blood Collection Devices Landscape

The blood collection devices landscape is undergoing a structural shift driven by safety, standardization, and decentralization. Healthcare providers are prioritizing safety-engineered needles, retractable lancets, closed transfer systems, and evacuated tube systems that reduce occupational exposure and support consistent sample quality. Global guidance on sharps safety and healthcare-associated infection prevention continues to influence purchasing policies, especially in hospitals and high-volume diagnostic laboratories.

A second major shift is the rise of patient-centric and minimally invasive collection. Capillary blood collection, microsampling, and dried blood spot approaches are gaining relevance in pediatrics, geriatrics, chronic disease monitoring, remote care, and clinical studies where convenience and low-volume sampling matter. This trend is supported by broader adoption of at-home testing, telehealth-linked diagnostics, and decentralized trial models.

The third shift is operational: laboratories and healthcare systems are demanding devices that minimize preanalytical errors. Tube additive accuracy, barcode compatibility, sample stability, fill-volume precision, and compatibility with automated analyzers are now central purchasing considerations. Sustainability is also influencing product development, with greater attention to packaging reduction, responsible plastics use, sterilization efficiency, and waste handling in regulated healthcare settings.

Cumulative Impact of Artificial Intelligence on Blood Collection Devices

Artificial intelligence is increasingly influencing the blood collection devices value chain, although its impact is most visible when combined with automation, digital identification, and laboratory information systems. In clinical settings, AI-enabled scheduling, demand prediction, and workflow orchestration can help reduce patient wait times, optimize phlebotomy staffing, and improve sample routing. Computer vision and sensor-based systems are also being explored to support vein visualization, collection verification, and error reduction in high-throughput environments.

Across laboratories, AI supports detection of preanalytical quality issues such as insufficient volume, clotting, labeling discrepancies, delayed transport, and hemolysis risk when paired with automated inspection and data capture systems. This strengthens the value proposition for blood collection devices designed with digital traceability, barcode readability, standardized tube geometry, and compatibility with automated processing lines.

In manufacturing and supply chains, AI contributes to quality analytics, predictive maintenance, demand planning, and lot-level traceability. These capabilities are especially important for products requiring sterility assurance, consistent material performance, and regulatory documentation. The cumulative impact of AI is therefore not a replacement of core collection devices, but an elevation of performance expectations: devices must increasingly fit into intelligent diagnostic ecosystems where safety, data integrity, traceability, and workflow efficiency are interconnected.

Key Regional Insights for Blood Collection Devices

Asia-Pacific is one of the most dynamic regions for blood collection devices due to expanding healthcare infrastructure, rising diagnostic test utilization, public health screening programs, and increasing access to private and public laboratory networks. China, India, Japan, South Korea, Australia, and ASEAN economies are strengthening diagnostic capacity, while chronic disease management, infectious disease surveillance, maternal health programs, and blood safety initiatives continue to support broad use of venous and capillary collection products. Procurement in the region is increasingly shaped by affordability, local manufacturing capacity, regulatory harmonization efforts, training needs, and demand for reliable safety-engineered devices.

North America remains highly advanced in safety compliance, laboratory automation, and quality management. The United States and Canada emphasize needlestick injury prevention, standardized phlebotomy practices, blood banking quality, and integration with electronic health records and laboratory information systems. Adoption is supported by high diagnostic testing intensity, a mature hospital network, widespread accreditation practices, and strong demand for evacuated blood collection tubes, safety needles, microcollection products, and specialty collection systems used in advanced testing.

Latin America is progressing through modernization of clinical laboratories, expansion of private diagnostic chains, and public health initiatives focused on infectious disease testing, maternal health, blood donation services, and chronic disease monitoring. Brazil and Mexico are important demand centers, while regional procurement often balances cost control with the need for improved sample quality, safer collection practices, reliable distribution, and standardized training for phlebotomy personnel.

Europe demonstrates strong regulatory discipline, occupational safety standards, and sustainability expectations. The region's healthcare systems emphasize product conformity, traceability, patient safety, post-market surveillance, and environmental responsibility, encouraging adoption of closed systems, safety-engineered sharps, and standardized collection workflows. Western European countries tend to lead in laboratory automation and digital laboratory integration, while Central and Eastern European systems continue upgrading diagnostic infrastructure and procurement quality standards.

The Middle East is investing in hospital modernization, medical tourism, specialty care, and national diagnostic capacity. GCC countries are particularly focused on high-quality healthcare infrastructure, digital health, and internationally aligned clinical standards, supporting demand for premium blood collection devices and automated laboratory-compatible products. Africa presents a different but significant opportunity profile, with needs centered on blood safety, infectious disease diagnostics, maternal and child health, outbreak preparedness, and decentralized testing. Progress in the region depends heavily on resilient distribution, affordability, healthcare worker training, donor-supported healthcare programs, cold-chain and logistics readiness, and devices suitable for varied infrastructure conditions.

Key Economic Group Insights for Blood Collection Devices

ASEAN countries are strengthening diagnostic networks through public health investment, private laboratory expansion, and growing chronic disease screening. The group's diversity creates varied adoption patterns: higher-income healthcare systems prioritize automation-compatible and safety-engineered blood collection devices, while emerging systems emphasize affordability, supply reliability, distribution reach, and training for standardized phlebotomy practices across urban and decentralized care settings.

The GCC is characterized by rapid healthcare modernization, hospital accreditation initiatives, digital health investment, and strong demand for premium clinical consumables. Blood collection device procurement in the GCC is influenced by international quality standards, infection control policies, advanced laboratory infrastructure, and the need to support specialty clinics, hospital laboratories, emergency care, and blood transfusion services.

The European Union places strong emphasis on regulatory conformity, medical device safety, environmental stewardship, and cross-border quality expectations. EU healthcare systems are attentive to medical device documentation, post-market surveillance, occupational health protections, and sustainability in healthcare procurement, which supports sustained preference for validated safety needles, evacuated tube systems, closed transfer devices, and standardized blood collection workflows.

BRICS economies represent a broad and influential demand base for blood collection devices, driven by large populations, healthcare access expansion, infectious and chronic disease testing needs, blood banking requirements, and increasing domestic manufacturing capabilities. China and India are especially important for scale and local production, while Brazil, Russia, and South Africa add demand through public health systems, hospital networks, laboratory modernization, and national priorities for supply resilience.

G7 countries generally show mature adoption of safety-engineered, automation-ready, and specialty blood collection devices. These markets focus on quality assurance, regulatory compliance, patient comfort, workforce protection, diagnostic accuracy, and digital integration across healthcare delivery. NATO countries overlap substantially with high-standard healthcare systems, where procurement resilience, supply chain security, emergency preparedness, and standardized medical logistics have gained strategic importance, particularly for essential clinical consumables including blood collection products.

Key Country Insights for Blood Collection Devices

The United States is shaped by high diagnostic testing volumes, strong occupational safety requirements, broad hospital and laboratory networks, and continued adoption of safety-engineered needles, evacuated tubes, blood bags, and specialty collection systems. Canada follows similar quality and safety priorities, with procurement influenced by public healthcare structures, infection prevention standards, laboratory consolidation, and national emphasis on equitable access to diagnostics. Mexico is advancing through private diagnostics expansion, public health testing, growing hospital investment, and proximity to North American medical supply chains, while Brazil remains a key Latin American market supported by hospital networks, blood banking needs, public health programs, and infectious disease and chronic disease testing demand.

In Europe, the United Kingdom emphasizes laboratory efficiency, patient safety, standardized diagnostics, and workforce protection across public and private care settings. Germany is distinguished by advanced clinical laboratories, strong manufacturing standards, robust quality systems, and demand for precision and automation-compatible blood collection products. France maintains strong emphasis on healthcare quality, infection control, regulated procurement, and traceable laboratory workflows. Russia's demand is tied to hospital infrastructure, public healthcare needs, blood service requirements, and domestic supply considerations. Italy and Spain support steady use of blood collection devices through mature healthcare systems, chronic disease management, blood donation services, hospital networks, and diagnostic laboratory capacity.

China is a major force in blood collection device demand and production, supported by hospital expansion, population-scale diagnostics, public health programs, domestic manufacturing, and growing regulatory sophistication. India's demand is driven by a large patient population, rising diagnostic access, chronic disease screening, infectious disease testing, and expansion of organized laboratory chains, with affordability, training, and supply reach remaining critical. Japan emphasizes high-quality, precision-engineered devices, patient comfort, and reliable preanalytical performance in an advanced healthcare environment. Australia prioritizes safety, quality, and standardized collection protocols across public and private care settings, while South Korea combines strong hospital infrastructure, advanced diagnostics, digital health readiness, and high laboratory standards, supporting demand for high-performance and automation-compatible blood collection products.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize safety-engineered product portfolios that address needlestick prevention, infection control, and compliance with occupational health expectations. Product development should focus on reducing hemolysis, improving fill accuracy, strengthening tube additive consistency, enhancing patient comfort, supporting low-volume and capillary sampling, and ensuring compatibility with laboratory automation and digital traceability systems.

Manufacturers and suppliers should build resilient, regionally diversified supply chains for critical materials, sterilization capacity, packaging, and distribution. Procurement teams increasingly value continuity of supply, lot-level documentation, validated quality systems, and rapid responsiveness during public health emergencies. Companies should also invest in clinician training, phlebotomy education, and clear instructions for use, as user technique remains a major determinant of sample quality and preanalytical reliability.

To compete in evolving diagnostic ecosystems, stakeholders should align blood collection devices with laboratory information systems, barcoding standards, automated analyzers, and emerging AI-enabled quality workflows. Sustainability should be embedded into product design and packaging strategies without compromising sterility, safety, or regulatory compliance. In emerging markets, leaders should balance affordability with durable quality, training support, and distribution models suited to decentralized healthcare delivery.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified healthcare, regulatory, clinical, and industry sources. The methodology prioritizes evidence from public health agencies, medical device regulatory authorities, occupational safety guidance, clinical laboratory standards, peer-reviewed literature, blood safety references, healthcare infrastructure indicators, and recognized diagnostics and laboratory medicine publications.

The analysis examines demand drivers, technology shifts, safety requirements, regional healthcare dynamics, diagnostic testing trends, and procurement priorities without using market sizing, market share, or forecasting. Regional, group, and country insights are synthesized through comparative evaluation of healthcare system maturity, laboratory infrastructure, regulatory direction, disease burden, public health testing needs, blood banking requirements, reimbursement context, workforce readiness, and supply chain considerations. Findings are validated through cross-source consistency checks and are presented as qualitative, data-backed strategic insights for decision-makers in the blood collection devices ecosystem.

Conclusion

Blood collection devices are evolving from routine clinical consumables into critical enablers of safe, standardized, and digitally connected diagnostics. The sector is being reshaped by safety regulations, automation-ready laboratory workflows, patient-centric sampling, decentralized care, blood safety priorities, and rising expectations for traceability and sample integrity. Artificial intelligence further amplifies these changes by improving workflow planning, quality monitoring, supply chain reliability, and data-driven laboratory operations.

Regional opportunities vary significantly: advanced healthcare systems emphasize automation, compliance, and premium safety features, while emerging regions prioritize access, affordability, resilient supply, and workforce training. Across all settings, the strongest strategic position will belong to stakeholders that combine device reliability, regulatory readiness, user-centered design, digital compatibility, and sustainable operations. As diagnostics remain central to modern healthcare, blood collection devices will continue to play an essential role in improving clinical decision-making, patient safety, transfusion readiness, and public health resilience.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Collection Devices Market, by Product Type

• 7.1. Introduction
• 7.2. Blood Bags
• 7.3. Blood Collection Needles
  • 7.3.1. Syringe Needles
  • 7.3.2. Vacuum Needles
• 7.4. Blood Collection Tubes
  • 7.4.1. EDTA Tubes
  • 7.4.2. Heparin Tubes
  • 7.4.3. Plasma Blood Tubes
  • 7.4.4. Serum Tubes
• 7.5. Blood Lancets

8. Blood Collection Devices Market, by Technology

• 8.1. Introduction
• 8.2. Automated Blood Collection Devices
• 8.3. Manual Blood Collection Devices

9. Blood Collection Devices Market, by Material

• 9.1. Introduction
• 9.2. Glass
• 9.3. Plastic
• 9.4. Rubber
• 9.5. Stainless Steel

10. Blood Collection Devices Market, by End Users

• 10.1. Introduction
• 10.2. Blood Donation Centers
• 10.3. Diagnostic Centers & Pathology Laboratory
• 10.4. Hospitals & Clinics

11. Blood Collection Devices Market, by Collection Method

• 11.1. Introduction
• 11.2. Venous Blood Collection
• 11.3. Capillary Blood Collection
  • 11.3.1. Fingerstick Collection
  • 11.3.2. Heel Stick Collection
• 11.4. Arterial Blood Collection

12. Blood Collection Devices Market, by Application

• 12.1. Introduction
• 12.2. Diagnostic Testing
  • 12.2.1. Routine Blood Testing
  • 12.2.2. Infectious Disease Testing
  • 12.2.3. Diabetes Monitoring
• 12.3. Blood Donation
• 12.4. Therapeutic Applications
• 12.5. Research Applications
  • 12.5.1. Clinical Trials
  • 12.5.2. Genomic Research
  • 12.5.3. Biomarker Analysis

13. Blood Collection Devices Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Blood Collection Devices Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Blood Collection Devices Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. AdvaCare Pharma
• 17.3. Agilent Technologies, Inc.
• 17.4. Avantor, Inc.
• 17.5. B. Braun SE
• 17.6. Becton, Dickinson, and Company
• 17.7. Bio-Rad Laboratories, Inc.
• 17.8. Biosigma S.p.A.
• 17.9. Cardinal Health, Inc.
• 17.10. Eurofins Scientific SE
• 17.11. Exelint International, Co.
• 17.12. F. Hoffmann-La Roche Ltd.
• 17.13. F.L. Medical S.r.l.
• 17.14. Greiner AG
• 17.15. GSI Group Holdings
• 17.16. Haemonetics Corporation by GVS S.p.A.
• 17.17. ICU Medical, Inc.
• 17.18. Medtronic PLC
• 17.19. Merck KGaA
• 17.20. Merit Medical Systems, Inc.
• 17.21. Nipro Medical Corporation
• 17.22. Retractable Technologies, Inc.
• 17.23. SAI Infusion Technologies
• 17.24. SARSTEDT AG & Co. KG
• 17.25. Shanghai Kohope Medical Devices Co., Ltd.
• 17.26. Siemens Healthineers AG
• 17.27. Terumo Corporation
• 17.28. Thermofisher Scientific Inc.